BPC-157 is one of the most talked-about peptides in sports medicine and regenerative health. Kiral now offers it. We think you should understand what the research does and doesn’t support before deciding whether it’s right for you, so this post summarizes the published literature as it stands today.
The short version
BPC-157 has a large body of positive preclinical (animal and cell) data but almost no rigorous human evidence. There are no randomized controlled trials of it in any musculoskeletal indication. The published human data consist of three small uncontrolled pilot studies and early-phase inflammatory bowel disease (IBD) trials that never went past phase II [1,2].
Current reviews conclude that BPC-157 should be treated as investigational until well-designed trials are done [2]. We agree, and that shapes how we approach it at Kiral (more on that below).
BPC-157 should be treated as investigational until well-designed trials are done.
What is BPC-157?
BPC-157 is a 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV). It was originally isolated from human gastric juice by Sikiric’s group in Croatia in the early 1990s [4,2]. It is stable in gastric juice, so animal studies have tested it orally as well as by injection [1,5].
The preclinical data
Most of the animal work is in rodents, and a large share comes from a single research group.
Gastrointestinal. Studies report healing of gastric and duodenal ulcers, colonic fistulas, and bowel anastomoses, along with improvement in esophagitis and models of short bowel syndrome [1,5].
Musculoskeletal.
- Ligament
In a rat medial collateral ligament transection model, intraperitoneal, oral, or topical dosing gave functional, biomechanical, and histologic improvement [1]. - Tendon
Rodents showed better Achilles tendon-to-bone healing [1]. - Muscle
Transected quadriceps muscle regenerated [1]. - Bone
A rabbit bone defect model showed better union [6,1].
Other models.
- Wounds and burns
Healing improved [1]. - Vascular
Outcomes were better in pulmonary hypertension and ischemia models, with protection against ischemia-reperfusion injury in liver, hippocampus, gut, and limb [1,7]. - Pain
Rats showed antinociceptive effects, but they lasted only about 2 hours [6]. - Organ protection
Liver protection and brain injury models have also been reported [2].
Proposed mechanisms
Researchers have proposed several ways BPC-157 might work:
- Angiogenesis and nitric oxide
VEGFR2–Akt–eNOS signaling and Src–caveolin-1–eNOS activation [6,2]. - Cell signaling
ERK1/2 signaling and Egr-1-mediated fibroblast activation [2,1]. - Tissue repair
TGF-β-driven type I collagen synthesis, FAK–paxillin-mediated migration of tendon cells, and increased growth hormone receptor expression in tendon fibroblasts [6,4]. - Anti-inflammatory and antioxidant effects
Lower IL-6, TNF-α, and malondialdehyde [7].
These are hypotheses drawn largely from animal and cell studies. They haven’t been confirmed in humans.
Citation: McGuire, F.P., Martinez, R., Lenz, A. et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 18, 611–619 (2025). doi:10.1007/s12178-025-09990-7
The human data
- PL 14736 in IBD and ulcerative colitis
Early-phase trials, up to phase II. Well tolerated, and development did not progress further. Efficacy was not established [1,5,7]. - Lee and Padgett 2021
Retrospective series of 12 patients with knee pain of unspecified cause, given an intra-articular injection (2 mL at 2,000 mcg/mL). Eleven of 12 (91.7%) reported relief for more than 6 months, and 3 of 4 given BPC-157 plus thymosin beta-4 improved. There was no control group. Outcomes relied on patient recall and unvalidated measures, so the risk of bias is high [1,6,8]. - Lee et al. 2024
Pilot of 12 women with interstitial cystitis that had failed pentosan, given a single 10 mg intravesical injection. Ten of 12 had complete symptom resolution, and 2 of 12 had about 80% improvement. No adverse events were reported. The study was uncontrolled and small [2,6]. - Lee and Burgess 2025
Two healthy adults received IV dosing up to 20 mg. There were no adverse events or lab abnormalities, and plasma levels were back to baseline within 24 hours. The sample was two people [2,6].
These results are interesting, but they are early signals, not proof. Without control groups, it’s impossible to separate a treatment effect from placebo response, natural recovery, or recall bias.
Safety
What has been seen. No adverse events have been reported in the human studies so far, and animal toxicology studies never reached a lethal dose [1,2,5].
Theoretical risks.
- Tumor growth
BPC-157 stimulates VEGF-driven angiogenesis, and high VEGF is linked to worse cancer outcomes. Some preclinical data point the other way, showing suppression of VEGF-driven tumor growth [8,2]. - Tendinopathy
New blood vessel growth is associated with worse function in chronic tendinopathy [8]. - Other
Excess nitric oxide and toxic metabolites are possible concerns [2].
Unknowns. Dosing, long-term safety, and drug interactions in humans have not been characterized. Product purity from unregulated sources is a separate concern [7,2].
Regulatory and anti-doping status
FDA. BPC-157 is not approved and carries the Category 2 designation described above [2].
WADA. Sources disagree. One describes a 2022 prohibition under S0 (non-approved substances) covering both competition and training. Another calls the 2022 listing temporary and says BPC-157 is not currently listed [2,3]. If you compete in tested sports, check the current WADA list directly.
Where Kiral fits in
We offer BPC-157 at Kiral, and we want to be clear about what that means. We are not claiming it is proven. The honest state of the evidence is that the animal data are encouraging, the human data are thin, and the major open questions are about dosing, long-term safety, and who benefits most.
Those gaps are the reason we think real-world data matter. By carefully tracking outcomes and safety in the people we care for, we aim to add to the body of literature, not replace controlled trials but give researchers and clinicians more to work with than a dozen-patient case series. If you’re considering BPC-157, talk with your Kiral clinician about whether it makes sense for your situation, what the risks are, and how we’ll monitor your response.
References
1. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593
2. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7
3. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185
4. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026:3635465261464420. doi:10.1177/03635465261464420
5. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-132. doi:10.2174/092986712803414015
6. Luansritisakul C, Chiang MC, Burns SL, Fonseca ACG. Peptides in regenerative medicine: a comprehensive review of clinical applications in tissue repair and chronic pain management. Curr Pain Headache Rep. 2026;30(1):109. doi:10.1007/s11916-026-01542-z
7. Yıldırım AK, Demirtaş H, Özer A, Arslan M. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Sci Rep. 2026;16(1):24375. doi:10.1038/s41598-026-55449-1
8. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0
This post is for educational purposes and isn’t medical advice. BPC-157 is an investigational substance and is not FDA-approved.